Tempera named associate professor in the Gene Expression & Regulation Program at Wistar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Italo Tempera was appointed associate professor in the Gene Expression & Regulation Program of The Wistar Institute Cancer Center.

Tempera is a molecular virologist with special expertise in the study of the Epstein Barr virus and how it regulates expression of its genes in the host cell during infection. Although EBV infection is very frequent and asymptomatic in most cases, in some individuals, especially those with a compromised immune system, it has a causative role in development of some types of cancer, including Burkitt’s lymphoma, nasopharyngeal carcinoma, and Hodgkin’s and non-Hodgkin’s lymphomas.

Research in the Tempera laboratory aims to disrupt the natural capacity of EBV to modulate its gene expression pattern as a new approach for treating EBV-associated cancers.

Tempera identified the main cellular factor that regulates the three-dimensional structure of the EBV genome and his laboratory focuses on the role of this factor, named CTCF, in the formation of loops in the virus DNA.

These loops allow distant segments of the genome to be in close proximity and regulate expression of EBV genes that are necessary for its life cycle within the cell. The team is also exploring how EBV chromatin loops are regulated by another cellular factor called PARP1. Given the role played by PARP1 in regulating cell metabolism after DNA damage, these studies could provide an exciting link between host cell metabolism and regulation of EBV chromatin structure.

The Tempera lab specializes in genomics techniques that allow them to study long-range interactions within chromatin, or the genetic material in which DNA and proteins are packed together to form chromosomes.

Tempera comes to Wistar from the Fels Institute for Cancer Research and Molecular Biology at the Lewis Katz School of Medicine of Temple University, where he established his lab in 2012 and was promoted to associate professor in 2017.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login